Drugs in Development for Hepatitis B Targeting cccDNA
Keywords:
virus de la hepatitis B, antivirales, inmunomoduladores, ADNcccAbstract
To completely eliminate HBV infection, the total eradication of covalently closed circular DNA (cccDNA), the mini-chromosome that provides the template for transcription of all viral mRNAs, would be required. Nuclear cccDNA accumulates in hepatocyte nuclei where it persists as a stable epigenome. Because the HBV genome is integrated into the host cell with this persistence of cccDNA a complete cure in which all cccDNA and integrated virus is eliminated is not something we currently have but is considered the ultimate aim of future therapies. The dozens of experimental CHB treatments currently being developed fall into two main categories: direct-acting antivirals that impede viral replication at a specific point and host-targeting agents that modify host cell function in a way that inhibits viral replication, including both immune modulators and agents that target other host functions. Each of these can target cccDNA directly or indirectly. Discussed here are agents currently in the clinical stage of development for CHB treatment that target cccDNA directly and those that may affect cccDNA indirectly.
Downloads
References
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403.
Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38 Suppl 2:S18-23.
Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56:422-433.
Marlen Ivon CF, Zaily DG, Conde-Eduardo Leda Patricia DS, et al. Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults. Curr Ther Res Clin Exp. 2017;85:15-19.
Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud. La Habana: MINSAP; 2018. Disponible en: http://www.sld.cu/sitios/dne/
Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50:661-662.
Rijckborst V, ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 2010;105:1762-1769.
Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067-1077.
Buster EHCJ, Janssen HLA. Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression. Neth J Med. 2006;64:175-185.
Lampertico P. The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy. Hepatology. 2015;61:1459-1461.
Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430.
Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457-1464.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-1751.
Pan CQ, Tong M, Kowdley KV, et al. High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:1047-1050 e1041.
Warner N, Locarnini S. Replication of hepatitis B virus. In: Boyer TD, Manns MP, Sanyal AJ, eds. Zakim and Boyer's Hepatology: A Textbook of Liver Disease. 6 ed. Philadelphia: Elsevier; 2012.
Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009;106:19975-19979.
Ohno M, Otsuka M, Kishikawa T, et al. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA. World J Gastroenterol. 2015;21:7084-7088.
Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-592.
Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001;75:311-322.
Gish RG, Given BD, Lai CL, et al. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015;121:47-58.
Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81.
Robaczewska M, Guerret S, Remy JS, et al. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther. 2001;8:874-881.
Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012;56:4277-4288.
Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221-1228.
Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21:121-131.
Wu G, Liu B, Zhang Y, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 2013;57:5344-5354.
Deres K, Schroder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003;299:893-896.
Cole AG. Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection. Curr Opin Pharmacol. 2016;30:131-137.
Jang JH, Kim JW, Jeong SH, et al. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat. 2011;18:84-90.
Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080-2086.
Kim SB, Song IH, Kim YM, et al. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol. 2012;18:6943-6950.
Tak WY, Yang JM, Kim BI, et al. A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naive chronic hepatitis B patients. Hepatol Int. 2014;8:375-381.
Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281.
Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368 e1361.
Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608 e1591-1592.
Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642-655.
Schluep T, Lickliter J, Hamilton J, et al. Safety, tolerability and pharmacokinetics of ARC-520 Injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clin Pharmacol Drug Dev. 2016:[Epub ahead of print].
Krebs K, Bottinger N, Huang LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145:456-465.
Wisskirchen K, Kah J, Malo A, et al. T cell receptor grafting allows virological control of Hepatitis B virus infection. J Clin Invest. 2019;129:2932-2945.
Kaneko M, Watashi K, Kamisuki S, et al. A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide. J Virol. 2015;89:11945-11953.
Ye X, Zhou M, He Y, et al. Efficient inhibition of hepatitis B virus infection by a preS1-binding peptide. Sci Rep. 2016;6:29391.
Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861-867.
Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009;49:1132-1140.
Pham EA, Perumpail RB, Fram BJ, et al. Future therapy for hepatitis B virus: role of immunomodulators. Curr Hepatol Rep. 2016;15:237-244.
Funk E, Kottilil S, Gilliam B, et al. Tickling the TLR7 to cure viral hepatitis. J Transl Med. 2014;12:129.
Chang J, Guo JT. Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Res. 2015;121:152-159.
Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015;62:1237-1245.
Wu J, Huang S, Zhao X, et al. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol. 2014;88:10421-10431.
Jo J, Tan AT, Ussher JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 2014;10:e1004210.
Huang LR, Wohlleber D, Reisinger F, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol. 2013;14:574-583.
Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144:1508-1517, 1517 e1501-1510.
Gane EJ, Lim YS, Gordon SC, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015;63:320-328.
Korolowicz KE, Iyer RP, Czerwinski S, et al. Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B. PLoS One. 2016;11:e0161313.
Barnes E. Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol. 2015;204:79-86.
Weng M, Zeng WZ, Wu XL, et al. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure. Virol J. 2013;10:277.
Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002;195:1089-1101.
Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 2014;3:e216.
Karimova M, Beschorner N, Dammermann W, et al. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep. 2015;5:13734.
Dong C, Qu L, Wang H, et al. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015;118:110-117.
Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids. 2014;3:e186.
White MK, Hu W, Khalili K. The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med. 2015;19:255-262.
Haapaniemi E, Botla S, Persson J, et al. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24:927-930.
Ihry RJ, Worringer KA, Salick MR, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24:939-946.
Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36 Suppl 1:85-92.
Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull. 2015;116:79-91.
Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65:835-848.
Al-Mahtab M, Bazinet M, Vaillant A, et al. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLoS One. 2016;11:e0156667.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Archivos Cubanos de Gastroenterolog?a
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
La revista reconoce a las personas que firman como autores siempre y cuando estos cumplan con los criterios establecidos universalmente para los autores de los art?culos cient?ficos. Regularmente se solicitar? a los autores de art?culos originales, env?en la declaraci?n de autor?a firmada por cada uno de ellos y donde se explique su rol dentro de la investigaci?n. El comit? editorial se reserva el derecho de aceptar determinados autores en relaci?n con el rol declarado y la envergadura de la investigaci?n.
Esta revista protege los Derechos de autor desde el mismo momento en que se realiza el env?o. Sin embargo, cede parte de los derechos patrimoniales de autor al exhibir una licencia Creative Commons 4.0 (cc-by-nc), que permite el uso de la obra para compartir (copiar y redistribuir el material en cualquier medio o formato) y adaptar (remezclar, transformar y construir a partir del material) siempre y cuando se haga menci?n exclusiva a la publicaci?n en la revista como fuente primaria. ?Sin embargo, no podr? comercializar con ella.
?
